ICMR reviewing use of tocilizumab for COVID-19 treatment
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The government is reconsidering the inclusion of tocilizumab in its treatment protocol for Covid-19 after new evidence emerged that it does not improve the condition of people with the disease.

Tocilizumab (Roche's Actemra) is part of the health ministry’s clinical management protocol for Covid-19 under investigational therapies for patients with moderate symptoms of the illness.

But the difference of opinion has emerged in the national task force of ICMR over its inclusion after Roche said in July that the phase III COVACTA study of Actemra®/RoActemra® (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe Covid-19 associated pneumonia.

“While many experts believe that tocilizumab should be dropped from the treatment protocol, there are some who believe that the drug should be made available with caveats,” a member of the ICMR task force told ET on condition of anonymity. “Hence, the discussion has not concluded.” The meeting was held last week.

“Many cited the literature which did not show any remarkable results, with many studies showing no benefit from the drug,” said another member, adding that some in the task force believes that the drug has the potential to benefit a certain subgroup of patients if given at the right time.

“The studies cited by them suggest that the drug shortens the time of discharge without any increase in adverse effects. Hence, they suggested that tocilizumab should not be removed in haste,” the member said.

The task force is yet to take a decision in this regard and may review the issue again.

Source: https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/icmr-reviewing-use-of-tocilizumab-for-covid/articleshow/77986162.cms
Dr. T●●●●z H●●●●●●i and 3 others like this4 shares
Like
Comment
Share